Citations |
(1) Rao C.N., et al., 1995, Arch. Biochem. Biophys. 317:311-314. (2) Tanaka Y., et al., 2004, Invest. Ophthalmol. Vis. Sci. 45:245. (3) Rollin J., et al., 2005, Br, J. Cancer 92:775. |
Background |
Tissue Factor Pathway Inhibitor 2 (TFPI2) is also known as placental protein 5 (PP5) and retinal pigment epithelial cell factor 1 (REF1), is a member of the Kunitz-type serine proteinase inhibitor family, is a structural homologue of tissue factor pathway inhibitor (TFPI). TFPI2 is highly abundant in the full-term placenta and widely expressed in umbilical vein endothelial cells, liver, placenta, heart, pancreas, and maternal serum at advanced pregnancy. TFPI2 may play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa and has no effect on thrombin. Reduced synthesis of TFPI-2 has been related to numerous pathophysiological processes such as inflammation, angiogenesis, atherosclerosis, retinal degeneration and tumor growth / metastasis. |